PureTech HealthPRTC
About: PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
Employees: 90
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.12% less ownership
Funds ownership: 0.14% [Q2] → 0.01% (-0.12%) [Q3]
33% less funds holding
Funds holding: 6 [Q2] → 4 (-2) [Q3]
54% less capital invested
Capital invested by funds: $1.28M [Q2] → $593K (-$683K) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Research analyst outlook
We haven’t received any recent analyst ratings for PRTC.
Financial journalist opinion
Based on 3 articles about PRTC published over the past 30 days
